Second-Generation (Atypical) Antipsychotics and Metabolic Effects

By John W. Newcomer. CNS Drugs, 2005

1,517 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Neurology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/dae401d63b72062fd835a95fc7129904571e7caf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. F. Alsaraj
2. Marc A. F. De Hert
3. Hans-Jürgen Möller
4. John W. Newcomer
5. I. Graham

In Neurology

1. F. Alsaraj
2. Marc A. F. De Hert
3. Hans-Jürgen Möller
4. B. Fischer

In Psychiatry and Mental health

1. F. Alsaraj
2. Marc A. F. De Hert
3. Christoph U. Correll
4. Hans-Jürgen Möller
5. I. Graham

Citations in the corpus

• Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) (2009, background): “Antipsychotics interact with many different brain receptors involved with appetite regulation, the most important of which are the histamine H1 receptor, 5-HT2c receptor and b3 and a1 adrenergic receptors [5,71,96,99,100,116,117,130].”
• Pathogenesis of Type 2 Diabetes Mellitus (2015, background): “Clozapine Olanzapine Wight gain [172, 173] and adiposity [174] Risk of hyperglycemia is more in patients with obesity, age, ethnic status, and certain neuropsychiatric conditions [173].”
• The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. (2010, background): “The available empirical evidence continues to support the use of clozapine in people who have not responded to adequate treatment with FGAs.1,2 There is new evidence to suggest that clozapine is more effective than other SGAs in people who have failed to adequately respond to either an FGA or SGA.9,”
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, background): “…risk factors (e.g., smoking, reduced physical activity, diabetes, hyperlipidemia), the risk of obesity, weight gain and metabolic side effects is increased, with a consequent rise in cardiovascular morbidity and mortality (Colton and Manderscheid 2006; Marder et al. 2004; Newcomer 2005; 2007).”
• Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011, background): “They are more likely to be overweight or obese, to have DM, hypertension, or dyslipidemia and to smoke (25,95,229,178,305-308).”